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Introduction and Methods: We report 20 patients aged 18–24 years from Latvia with diphtheritic
polyneuropathy. All lived in a closed community and 80% were known to have been fully vaccinated
against diphtheria until at least 14 years old. Diphtheria antitoxin had been administered within 3 days of
the onset of upper respiratory tract infection in 16 patients and 15 received antibiotics.
Results: Neurological symptoms developed after a median of 43 days (range 35–58) compared to only
10 days in previous studies of unvaccinated patients. All showed evidence of mild limb polyneuropathy
with electrophysiological evidence of polyneuropathy. Only 30% showed early bulbar abnormalities
compared to the usual rate of over 95% in diphtheritic polyneuropathy. However, 45% had later bulbar
deterioration coinciding with the limb polyneuropathy.
Conclusions: These patients show that an attenuated form of polyneuropathy of later onset, with less
prominent early bulbar features, can occur in patients vaccinated against diphtheria according to schedule
but living in a closed community in a country where diphtheria remains endemic.
I
t is generally considered that a high rate of vaccination will
protect a community against epidemic diphtheria. When
diphtheria re-emerged in the late 1980s and early 1990s in
Eastern Europe and Russia, including Latvia, cases of
diphtheritic polyneuropathy (DP) occurred. Three major
factors contributed to this Latvian diphtheria epidemic:
declining childhood immunisation rates, declining immunity
in previously vaccinated adults, and the importation of
diphtheria from neighbouring countries. The epidemic in
Latvia led to a mass vaccination programme of adults and
children in 1995. In Latvia since 1986 the recommended
vaccination schedule with diphtheria toxoid had consisted of
a primary series of diphtheria and tetanus toxoids and
pertussis vaccine (DTP) administered at 3, 4.5, and 6 months
of age with booster doses at 18 months, 9, and 16 years of
age.1 Various vaccine preparations were used with differing
diphtheria toxoid contents. Despite these vaccination mea-
sures, cases of diphtheria continue to occur in Latvia, with a
secondary peak of 574 cases between 1998 and 2000, with 38
deaths.2 In 2000, 231 diphtheria cases were registered at the
Infectology Centre in Riga out of a Latvian total of 264; the
majority (149) of these cases were cadets, soldiers, and other
defence personnel from a single closed community.3
Polyneuropathy is the most common severe complication
of diphtheria infection.4 It follows 10% of moderate infections
and up to 75% of severe infections.5 Our earlier study of
Latvian adults aged 41–60, with uncertain vaccination
histories, showed DP occurring in 15% of patients admitted
to hospital.6 Bulbar symptoms occurred in 98% of these DP
patients and there was respiratory involvement in 30%, while
limb symptoms were mild or absent in 30%. Of the 149
Latvian military personnel registered with diphtheria in 2000,
polyneuropathy occurred in 20, of whom 80% were known to
have been fully vaccinated against diphtheria in childhood
and adolescence. We report the clinical manifestations and
severity of the acute polyneuropathy in these young men
from a closed military community.
METHODS
Of 149 (aged 18–40 years) diphtheria infected cadets,
soldiers, and defence personnel, 20 were studied because of
neuropathic symptoms. Suspected, probable, or confirmed
cases of diphtheria were diagnosed according World Health
Organization criteria.7 Available vaccination records were
reviewed for vaccination dates, number of doses, lot
numbers, and type of diphtheria toxoid formulation, for
example, DT (high antigen toxoid, 12 Lf) as given in
childhood or Td (low antigen toxoid, 2 Lf) given as an
adolescent booster.
The severity of the polyneuropathy was assessed accord-
ing to a scale (motor disability grades 0–6, bulbar dysfunc-
tion grades 0–3, sensory symptoms grades 0–2) used
previously.6 Seventeen subjects underwent nerve conduc-
tion studies using standard methods at a skin temperature
of >34 C̊ including motor conduction along four nerves
(median, ulnar, tibial, and peroneal) and sensory conduc-
tion along four or five nerves (median, ulnar, tibial, sural,
and peroneal) using a Multiliner E measuring station to
record EMG data (Jaeger-Toennies, Hoechburg, Germany). A
motor or sensory nerve conduction velocity (SNCV) of




The 20 patients with DP were 18–24 year old males with an
average age of 19.7 years. Bacterial culture for Corynebacterium
diphtheria (b.v. gravis) was positive in 10; it should be noted
that antibiotic administration had been common prior to
admission to hospital as prophylaxis, or on suspicion of
diagnosis, during the 3 days over which this diphtheria
outbreak developed. All 20 showed pharyngeal or tonsillar
evidence of diphtheritic infection, two neck oedema, and 17
electrocardiographic myocarditis. Most (15 or 75%) were
hospitalised in the Infectology Centre within the first 3 days
of the localised infection. Five others were admitted from
the 6th to 30th days. A total of 14 patients (70%) required
Abbreviations: DML, distal motor latency; DP, diphtheritic
polyneuropathy; DTP vaccine, diphtheria and tetanus toxoids and






















treatment in specialised neurological departments.
Antibacterial therapy was administered in 15: erythromycin
in 12 (60%) and benzyl penicillin in three (15%). Diphtheria
antitoxin was administered in 16 cases (80%) within 3 days
of the first signs of disease; it was not administered in four
(20%) due to late hospitalisation.
A total of 16 patients (80%) had been fully vaccinated
against diphtheria including a booster given at age 14–16.
Two patients (10%) were incompletely vaccinated and one
patient (5%) did not recall vaccination; all three showed
‘‘protective’’ levels of IgG antibodies against diphtheria
toxoid (ranging from 0.19 to .1 IU/ml). Vaccination records
were unavailable for one patient (5%) who had low IgG
antibody levels (0.08 IU/ml). The last booster dose had been a
median of 4.1 years (range 1–8) previously. Detection of
antibody response to diphtheria toxin was performed on
admission and showed IgM negative in all (100%), and IgG
.1.0 IU/ml in 13 (65%), 0.1–1.0 IU/ml in six (30%), and
0.08 IU/ml in one (5%).
Neurological features
The first neurological symptoms developed a median of
43 days (range 35–58) after the onset of localised tonsillar
and pharyngeal diphtheria. Only seven patients (30%)
manifested early local bulbar symptoms after the onset of
infection with hoarseness in three and dysphagia in four.
Late bulbar deterioration coinciding with limb polyneuro-
pathy occurred in nine (45%): in two as grade 2 bulbar
dysfunction (moderate dysphagia, nasal voice, palatal par-
esis) and in seven as grade 1 (minor symptoms and signs
without dysphagia).
All 20 had neuropathic limb symptoms or signs: 10
(50%) experienced grade 1 disability in walking; two
(10%) showed mild weakness of ankle dorsiflexion; 19
(95%) had distal limb tingling; 15 (75%) leg pain; seven
(35%) arm pain; and 13 (65%) altered pain and touch
sensation of ‘‘sock’’ distribution (hypoaesthesia in nine,
hyperaesthesia in four). Ten (50% of patients) had dimin-
ished tendon reflexes.
The four patients with an uncertain or incomplete
vaccination history lay within the same spectrum as the
other patients with onsets ranging from 37 to 55 days with
only one manifesting bulbar symptoms.
Improvement of neurological symptoms and signs gener-
ally occurred within 30 days of their onset.
Nerve conduction studies
Evidence of mild conduction slowing was found in all 17
patients. Sensory action potential amplitudes were normal in
all.
Four patients (group 1) had decreased SNCV in leg nerves:
tibial (four; average 41 m/s; range 35–44); sural (two;
average 37 m/s; range 32–42); and peroneal (two; average
36 m/s; range 33–40).
Eight patients (group 2) had slowed motor conduction
velocity (MCV) and SNCV in leg nerves only. Distal motor
latency (DML) was prolonged in the peroneal nerve in seven
patients (average 4.3 m/s; range 4.0–4.9; normal (3.8).
Decreased MCV occurred in the peroneal nerve (average
40 m/s; range 37–44) and the tibial nerve (one; 42 m/s).
SNCV was reduced in the tibial nerve (seven) to 35 m/s
(range 29–45) and in the peroneal (five) to 43 m/s (range 38–
45).
Five patients (group 3) had slowed MCV and SNCV in
nerves of both arms and legs. Prolonged DML occurred in the
peroneal nerve (four; average 5.1 m/s; range 4.1–6.3) and in
the tibial (three; average 6.7 m/s; range 6.5–7.2). MCV was
decreased in the forearm median nerve (one; 44 m/s) and in
the peroneal (three; average 42 m/s; range 40–45). Slowed
SNCV occurred in the tibial nerve (four; average 29 m/s;
range 26–31) and in the median (two; average 46 m/s; range
40–44).
In summary, there was neurophysiological evidence of
mild sensory motor polyneuropathy in legs alone in eight
(47%) patients, mild generalised polyneuropathy in five
(29%), and mild sensory neuropathy restricted to the legs
in four (24%).
DISCUSSION
These recently vaccinated young adults from a closed
community with diphtheria exhibited a milder form of
polyneuropathy than previously associated with diphtheria.6
There was a lesser incidence of early bulbar weakness and
subsequent limb symptoms were less severe. The previously
described phenomenon of secondary, or late, bulbar dete-
rioration at the time of limb polyneuropathy6 occurred at a
similar frequency as previously (45%) but was also less
severe. The onset of this attenuated polyneuropathy occurred
later (median 43 days; range 35–58) in these previously
vaccinated patients with attenuated disease compared to the
median of 10 days (range 2–50 days) that we had observed
previously.6 In part, this increased latency may reflect the
greatly reduced incidence of early bulbar symptoms (only
30%) in these patients with attenuated disease compared to
98% in our previous study. The latency of onset of generalised
neurological symptoms in these recently vaccinated patients
was a median of 43 days, not dissimilar to the latency to
occurrence of first limb symptoms (median 37 days) noted
previously.
The recurrence of diphtheria in Latvia in the 1990s was
acknowledged as an epidemic. After 17 years without
diphtheria, cases had reappeared in 1986.1 During this initial
epidemic, the incidence increased until 1994, with the disease
usually occurring in middle aged adults. The maximum
incidence was reached in 1995 with 369 cases and 27 deaths,
a rate of 14.6 per 100 000. In 1995, the vaccination schedule
was modified so that the second and third diphtheria booster
doses were given at 7 and 14 rather than at 9 and 15 years of
age. A mass vaccination campaign was initiated, targeted at
providing at least 90% of adults between the ages of 25 and
60 with at least one booster dose of diphtheria toxoid vaccine.
Single booster vaccination in Latvia produced protective
antibody levels in 81% of adults compared to 38% prior to
vaccination.8 These immunisation campaigns in Latvia
succeeded in delivering three doses of diphtheria toxoid to
approximately 55% of adults between 1995 and 1997.
Recorded cases of diphtheria dropped to only 42 in 1997.1
However, cases began to increase again between 1998 and
2000, including these 20 military cadets with polyneuro-
pathy, constituting 13% of the 149 cadets and other defence
personnel who developed diphtheria in 2000.
There could be various reasons for the attenuated severity,
delayed onset, and lesser bulbar symptoms of the diphtheritic
neuropathy occurring in these young adults with a history of
recent booster vaccination. The protective effects of vaccina-
tion with diphtheria toxoid probably attenuated the effects of
the exotoxin produced by pharyngeal infection. Renewed
awareness, both of the diagnosis of diphtheria and of the
need for early antitoxin administration, led to most of these
patients receiving antitoxin within the first 3 days of disease;
this therapeutic administration of antitoxin may have
attenuated the neurological disorder. It should be noted that
our previous study suggested that antitoxin was not effective
in preventing polyneuropathy if given after the first 2 or 3
days.6
The continued occurrence of diphtheria in Latvia, despite
renewed and intensive vaccination programmes, raises a
few points. First, doctors need to be aware of this diagnosis




















in patients with neurological bulbar or limb symptoms,
particularly if there is a history of travel to endemic regions.
Second, a booster vaccination in recent years does not
exclude diphtheria as a cause of polyneuropathy. Third, the
continued occurrence of diphtheria emphasises the need for
public health measures to ensure that adults receive booster
vaccinations with toxoid because of waning immunity and a
decline in previously provoked antibody levels.9 10
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